The study will mark the fourth ongoing clinical trial for Kazia's GDC-0084 drug candidate, with each trial treating different forms of brain cancer.
Showing 25 of 1839
The restructure will enable the company to improve working capital management and reduce cash burn through reduction in headcount.
If Bronchitol is approved later this year, Pharmaxis is down to receive US$10 million.
The company will begin recruitment for the upcoming dose expansion cohort immediately.
The company’s O2 Vent Optima device was launched in both Australia and Canada during the March quarter.
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews.
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor.
Along with the entitlement offer, Paradigm has raised $51.6 million via a placement to professional, institutional and sophisticated investors.
The company’s thesis is that pancreatic enzymes can be used to halt the spread of cancer
The capital raising has attracted a number of international institutional investors.
The company is currently fully funded in supporting all clinical research programs.
OA remains the most common form of joint disease globally, affecting over 30 million adults in the US alone.
In conjunction with the capital raise, Paradigm has revealed that it has successfully met the primary and secondary endpoints of its phase 2b trial in OA of the knee.
Hong Kong investor Sun Bright Holdings will contribute up to $18 million for cancer vaccine and immunotherapies development.
The Medical University Vienna and Imugene are working to develop mimotope based cancer vaccines.
The company’s automated plate assessment system (APAS) is an innovative platform technology that automates culture-plate screening and interpretation.
Data shows combining KEY-Vaxx and B-Vaxx is more effective than KEY-Vaxx alone.
Notification of the intention to grant a patent will increase the commercial value of the évolis® brand beyond sales.
The company hopes to improve its share price with ADAPT technology successes.
Over the past year, shares have come from 29 cents to be trading at around $1.90.
The US Food and Drug Administration has convened a meeting of the Pulmonary-Allergy Drugs Advisory Committee on May 8, 2019.
The company had a pre-investigational new drug (IND) meeting with the FDA last month.
The first patient was dosed in the Eastern European country of Moldova.
CE marking is a certification mark that indicates conformity with European health, safety, and environmental protection standards.